According to sources:
“Invaluable in providing us with solid, practical advice in complex transactions”
“Very focused on achieving the client’s objectives”
Chambers USA 2021

“Extremely bright and responsive”
“Has a good temperament and is excellent in negotiations” 
Chambers USA 2020

A. Peter Harwich

New York
  • 1271 Avenue of the Americas
  • New York, NY 10020
  • USA

Peter Harwich advises leading US and international public companies, as well as their boards of directors, on their most significant M&A transactions and other sensitive corporate matters.

Mr. Harwich brings experience representing clients in high-stakes transactions across a variety of industries, with a particular focus on the technology, healthcare, consumer products, and financial services sectors. He provides commercially focused counsel to clients in connection with public and private M&A matters, joint ventures and strategic alliances, securities laws, corporate governance, and stock exchange requirements.

Mr. Harwich also routinely represents issuers and underwriters on SEC-registered capital markets transactions.

Mr. Harwich's experience includes advising:

  • London Stock Exchange Group in its pending US$1.1 billion divestiture of BETA+ to Clearlake Capital Group and Motive Partners
  • Inovalon, the NYSE-listed provider of data-driven healthcare analytics, in its US$7.3 billion all-cash acquisition by an equity consortium led by Nordic Capital
  • The independent directors, special committees, and conflicts committee of NYSE-listed Athene Holding in connection with various matters, including Athene’s pending US$11 billion stock-for-stock merger with NYSE-listed Apollo Global Management, Athene’s US$1.55 billion share exchange transaction with Apollo Global Management, its acquisition together with Apollo Global Management of PK AirFinance from GECAS involving US$3.6 billion in aviation finance assets, and its establishment of strategic capital vehicle Athene Co-Invest Reinsurance Affiliate (ACRA) with US$3 billion in capital commitments
  • The independent directors of NYSE-listed First Data in its US$22 billion stock-for-stock merger with Fiserv
  • DXC Technology in its US$5 billion sale of its US State and Local Health and Human Services business to Veritas Capital, its US$525 million sale of its healthcare provider software business to Dedalus Group, its US$2 billion all-cash acquisition of NYSE-listed Luxoft Holding, and the US$4.4 billion tax-free spin-off and subsequent three-way merger of its US government IT services business with Veritas Capital portfolio companies Vencore and KeyPoint Government Solutions in a Reverse Morris Trust transaction to form NYSE-listed Perspecta
  • Computer Sciences Corporation on its US$14 billion Reverse Morris Trust transaction involving Hewlett Packard Enterprise's global enterprise services segment that resulted in the formation of DXC Technology, on its approximately US$6 billion spin-off of CSRA and special dividend and approximately US$2.3 billion merger of CSRA and SRA International
  • SAP on some of its largest transactions, including its US$3.4 billion tender offer for NYSE-listed SuccessFactors and its approximately US$6.7 billion tender offer for NASDAQ-listed Business Objects
  • Thomson Reuters on numerous transactions, including the US$17 billion public acquisition of NYSE-listed Reuters Group; the acquisitions of Integration Point, Practical Law Company, Manatron, Paisley, and Pangea3; and the divestiture of various businesses, including its sale of its Intellectual Property & Science segment to Onex and Baring for US$3.55 billion; its US$390 million sale of its Corporate Services unit to Nasdaq; and the sales of its Legal Managed Services, Penn-Foster, and Property Tax Services units
  • Deutsche Börse on its US$1.1 billion sale of International Securities Exchange Holdings to NASDAQ
  • GE on numerous transactions, including the US$3.8 billion sale of its Advanced Materials business, its US$1.2 billion public acquisition of NASDAQ-listed IDX Systems, its US$1.1 billion public acquisition of NASDAQ-listed Vital Signs, and its sale of 81% of GE Homeland Protection to SAFRAN for US$579 million
  • D.E Master Blenders (the spin-off resulting from Sara Lee's separation into two public companies) in its approximately US$9.8 billion public acquisition by a consortium led by Joh. A. Benckiser
  • L’Oréal in its acquisition of Youth to the People, a California-based skincare company

*Certain matters were handled prior to joining Latham

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.